The pharmaceutical company Viking has recently become one of the most volatile stocks on Wall Street due to the announcement ...

It seems like every day a new study emerges linking Ozempic and similar drugs to new health benefits. Ozempic is part of a drug class known as GLP-1 medications, which mimic gut hormones that help ...

Rather than bribing and wheedling physicians to pretty-please-prescribe-our-drug, websites allow companies to deal drugs ...

The Danish company’s share price rise of 7 per cent this year lags far behind its rival Eli Lilly’s 36 per cent, as the US company has gradually increased its share of the obesity and diabetes market ...

Obesity pill data released by Viking Therapeutics Inc and AstraZeneca Plc at a big conference foreshadowed an increasingly ...

Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.

AstraZeneca PLC shed GBP15 billion of market capitalization on Tuesday, after investors were underwhelmed by early data from a trial of a weight-loss pill. The company (UK:AZN) said its lead product ...

AstraZeneca’s new obesity pill, licensed from China’s Eccogene last year, has shown initial promise in early-stage trials.

Viking Therapeutics announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.

Obesity pill data released by Viking Therapeutics Inc. and AstraZeneca Plc at a big conference foreshadowed an increasingly competitive landscape for weight-loss therapies, sending down shares of ...

Powerful weight-loss drugs like Wegovy and Zepbound have driven nearly $1 trillion in market-capitalization gains, with most ...